# Original Article

Check for updates

# Comparison of the presentation of atopic dermatitis induced by trinitrochlorobenzene and house dust mite in NC/Nga mice

Yoon-Hwan Kim <sup>[b]</sup><sup>1,†</sup>, Tae Hyeong Kim <sup>[b]</sup><sup>2,†</sup>, Min Soo Kang <sup>[b]</sup><sup>2</sup>, Jin-Ok Ahn <sup>[b]</sup><sup>1</sup>, Jung Hoon Choi <sup>[b]</sup><sup>2,\*</sup>, Jin-Young Chung <sup>[b]</sup><sup>1,\*</sup>

<sup>1</sup>Department of Veterinary Internal Medicine and Institute of Veterinary Science, College of Veterinary Medicine, Kangwon National University, Chuncheon 24341, Korea <sup>2</sup>Department of Anatomy and Institute of Veterinary Science, College of Veterinary Medicine, Kangwon National University, Chuncheon 24341, Korea

# ABSTRACT

**Background:** Atopic dermatitis (AD) is a common chronic inflammatory skin disease. To understand AD, there have been many trials establishing AD animal models. Although various trials to establish AD animal models have been existed, even the mechanisms of AD in animal models are not enough clarified.

**Objectives:** This study assessed AD characteristics induced in Nishiki-nezumi Cinnamon/ Nagoya (Nc/Nga) mice following trinitrochlorobenzene (TNCB) treatment for different periods and house dust mite (HDM) treatment to compare each model's immunological patterns, especially with cytokine antibody array tool.

**Methods:** In this study, we exposed Nc/Nga mice to TNCB or HDM extract to induce AD. Nc/Nga mice were divided into 4 groups: control, TNCB 2 weeks-treated, TNCB 8 weekstreated, and HDM-treated groups. After AD induction, all mice were evaluated by serum immunoglobulin E (IgE) concentration and serum cytokine antibody assays, scoring of skin lesions, scoring of scratching frequency, and histological analysis.

**Results:** The results showed significant differences between groups in serum IgE concentration, skin lesion scores, and scratching frequency. The analysis results for serum cytokine antibody arrays showed that in the TNCB 8 weeks- and HDM-treated groups, but not in the TNCB 2 weeks-treated group, expressions of genes related to the immune response were enriched. Among the histological results, the skin lesions in the HDM-treated group were most similar to those of AD.

**Conclusions:** We confirmed that immunological pattern of AD mice was markedly different between HDM and TNCB treated groups. In addition, the immunological pattern was quietly different dependent on TNCB treated duration.

Keywords: Atopic dermatitis; Nc/Nga mouse; trinitrochlorobenzene; house dust mite; cytokines

# INTRODUCTION

Atopic dermatitis (AD) is a common chronic inflammatory skin disease accompanied by clinical signs such as severe pruritus, dryness, erythema, edema, excoriation, or

# OPEN ACCESS

Received: Jan 17, 2020 Revised: Apr 1, 2020 Accepted: Apr 12, 2020

### \*Corresponding authors: Jin-Young Chung

Department of Veterinary Internal Medicine and Institute of Veterinary Science, College of Veterinary Medicine, Kangwon National University, 1 Gangwondaehak-gil, Chuncheon 24341, Korea. E-mail: chungjinyoung@kangwon.ac.kr

# Jung Hoon Choi

Department of Anatomy and Institute of Veterinary Science, College of Veterinary Medicine, Kangwon National University, 1 Gangwondaehak-gil, Chuncheon 24341, Korea. E-mail: jhchoi@kangwon.ac.kr

<sup>+</sup>Yoon-Hwan Kim and Tae Hyeong Kim contributed equally to this study.

© 2020 The Korean Society of Veterinary Science

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:// creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

### **ORCID** iDs

Yoon-Hwan Kim D https://orcid.org/0000-0002-0727-9927 Tae Hyeong Kim D https://orcid.org/0000-0002-0938-0818



Min Soo Kang 🕩

https://orcid.org/0000-0002-1698-9445 Jin-Ok Ahn https://orcid.org/0000-0002-3300-6084 Jung Hoon Choi https://orcid.org/0000-0002-3725-4907 Jin-Young Chung https://orcid.org/0000-0001-6729-9834

#### Funding

This work was supported by Cooperative Research Program for Agriculture Science and Technology Development (Project No. PJ01395602), Rural Development Administration, Republic of Korea.

#### **Conflict of Interest**

The authors declare no conflicts of interest.

#### **Author Contribution**

Conceptualization: Chung JY; Data curation: Kang MS, Ahn JO; Formal analysis: Chung JY, Choi JH; Funding acquisition: Chung JY; Investigation: Kim YH, Kim TH; Methodology: Kang MS, Ahn JO; Project administration: Chung JY; Supervision: Chung JY, Choi JH; Validation: Chung JY, Choi JH; Visualization: Kang MS, Ahn JO; Writing - original draft: Kim YH, Kim TH; Writing -review & editing: Chung JY, Choi JH. lichenification. In human medicine, up to 20% of people suffer from AD [1]. Not only in human medicine but also in veterinary medicine, AD is a common dermatosis defined as a genetically predisposed inflammatory and pruritic skin disease [2].

The pathogenesis of AD can be summarized as follows [3-5]: allergens invade through a defective skin barrier and are then recognized by antigen-presenting cells, Langerhans cells, or dermal dendritic cells in the epithelium. In the acute phase, this is followed by the differentiation of T helper (Th) 0 cells into Th2 cells, while in the chronic phase Th0 cells differentiate into Th1 cells, accompanied by the release of various cytokines. These processes induce B cells to produce IgE, which, in turn, induce mast cells and eosinophils to stimulate degranulation, releasing several inflammatory mediators such as histamine, bradykinin, prostaglandin, and leukotriene. Meanwhile, Th2 cells migrate to the skin and release various cytokines to induce pruritus [6]. Scratching, a consequence of pruritus, induces mechanical injury and release of cytokines to disrupt the skin barrier and attract eosinophils to the skin layer. Many inflammatory cells can infiltrate skin tissue, and inflammatory cytokines released from inflammatory cells stimulate Th1 cell differentiation and activate cellular immunity [4,7].

During previous attempts to further the understanding of AD, there have been many studies into establishing AD animal models [8-10]. Those AD animal models can be categorized into 3 groups: 1) models induced by sensitizers; 2) transgenic mice which over-express or lack the expression of molecules; 3) mice that spontaneously develop AD-like skin lesions [11]. Nishiki-nezumi Cinnamon/Nagoya (Nc/Nga) mice are included in the latter group of mice that spontaneously develop AD-like skin lesions. Nc/Nga mice are members of a mutation strain developed at Nagoya University in Japan in 1997 and are the first AD mouse model to be reported [12]. The skin changes of Nc/Nga mice develop spontaneously under conventional conditions, not under specific-pathogen-free conditions, and the changes closely mimic human AD [13]. Some studies have suggested that exposure to a conventional environment is not sufficient to produce AD in NC/Nga mice; however, this can be resolved by applying a sensitizer to the surface of the skin, thus easily leading to AD [14]. Trinitrochlorobenzene (TNCB) and house dust mite (HDM) allergen are representative sensitizers. TNCB is a hapten that is commonly used to induce AD and has been thought to evoke a primarily Th1dominated response [11]. The HDM allergen is very common in real life. Clinical study had provided evidence that HDM allergen is associated with AD [9]. Dermatophagoides farinae is a representative HDM that can produce symptoms similar to those of AD. The HDM allergenrelated pathogenesis is unclear but it is reported that application of a HDM extract to the skin can increase the expressions of Th1/Th2/Th17 related cytokines [15].

Currently, there are few studies comparing the various AD animal models. In this study, we assessed AD characteristics induced in Nc/Nga mice following TNCB treatment for different periods (short period, 2 weeks and long period, 8 weeks) and HDM treatment to compare each model's immunological patterns.

# **MATERIALS AND METHODS**

## Animals

Eight-week-old female NC/Nga mice were purchased from Central Laboratory Animal Inc. (Korea). The mice were housed in an air-conditioned room maintained at  $24^{\circ}C \pm 2^{\circ}C$  and  $55\% \pm 15\%$  humidity. Protocols for care and use of animals in this study were in compliance with



guidelines and were approved by the Kangwon National University Institutional Care and Animal Use Committee (KW-180705-4).

Twenty NC/Nga mice (8-week-old females) were used during this study. Mice were assigned to one of 4 groups; control group, TNCB 2 weeks-treated group, TNCB 8 weeks-treated group, and the HDM-treated group (n = 5 in each group).

# Induction of AD in the NC/Nga mice

TNCB and HDM were used to induce AD [12,16]. For the control group, the hair on the back of the NC/Nga mice was shaved using an electric shaver, followed by treatment with saline twice a week for 4 weeks. For the TNCB 2 weeks-treated group, the hair on the back of the NC/Nga mice was shaved using an electric shaver, followed by treatment with 100  $\mu$ L of 2% TNCB (Sigma-Aldrich, USA) 3 times a week for 2 weeks. For the TNCB 8 weeks-treated group, the hair on the back of the NC/Nga mice was shaved using an electric shaver, followed by treatment with 100  $\mu$ L of 2% TNCB (Sigma-Aldrich, USA) 3 times a week for 2 weeks. For the TNCB 8 weeks-treated group, the hair on the back of the NC/Nga mice was shaved using an electric shaver, followed by treatment with 100  $\mu$ L of 2% TNCB 3 times a week for 2 weeks. After then 100  $\mu$ L 0.2% TNCB was applied 3 times a week for 6 weeks in the TNCB 8 weeks-treated group. TNCB was prepared by dissolving TNCB in a 4:1 mixture of acetone and olive oil.

For the HDM-treated group, the hair on the back of the NC/Nga mice was shaved using an electric shaver, followed by treatment with 100  $\mu$ L of 4% (w/v) sodium dodecyl sulfate (SDS; Sigma-Aldrich, USA) to disrupt the skin barrier. After drying with 4% SDS, 100 mg/mouse of HDM allergen (HDM; Biostir Inc., Japan) was applied to the prepared skin area, with the HDM application repeated twice per week for 4 weeks (**Fig. 1**).

# Serum IgE concentration assay

Serum was collected from sacrificed mice, and the concentration of total IgE in the serum was measured by using an enzyme-linked immunosorbent assay (ELISA) kit (Fujifilm Wako Shibayagi Corporation, Japan). All of the ELISA procedures were performed following the manufacturer's instructions. Upon completion of the assay procedure, the plate was read at 450 nm using a SpectraMax ABS Plus Microplate Reader (Molecular Devices, LLC, USA). All of the ELISA analysis was replicated.

# Serum cytokine antibody array

Serum from 5 sacrificed mice in each group was pooled into one sample and 100  $\mu L$  of pooled serum was used for the array protocol. The concentration of sample was measured with BCA



Fig. 1. Scheme of AD induction in NC/Nga mice.

AD, atopic dermatitis; NC/Nga, Nishiki-nezumi Cinnamon/Nagoya; TNCB, trinitrochlorobenzene.



protein assay kit (Pierce,USA) using Multi-Skan FC (Thermo, USA). And the purity of sample was confirmed on ultraviolet (UV) spectrum. The pooled serum was diluted 1:10 and probed to determine the cytokine profile according to the manufacturer's instructions (RayBiotech, Inc., USA).

The slide scanning was performed using GenePix 4100A Scanner (Axon Instrument, USA). The slides were scanned at 10  $\mu$ m resolution, optimal laser power and photomultiplier tube. After got the scan image, they were quantified with GenePix Software (Axon Instrument). After analyzing, the data about protein information was annotated using UniProt DB. Relative fold changes were calculated by dividing the value obtained from the treated groups by that from the control group.

# Scoring of skin lesions

The extents of 1) erythema/hemorrhage, 2) scarring/dryness, 3) edema, and 4) excoriation/ erosion were individually scored as 0 (none), 1 (mild), 2 (moderate), and 3 (severe). The total skin score was the sum of the individual scores [17]. Scoring was performed every week during the experiment period. All of the scoring was fulfilled by 2 different observers repeatedly for the exclusion of bias.

# Scoring of scratching frequency

The frequency of scratching on facial or dorsal skin was determined based on counting the number of scratches in a 5-min period. The methodology used for behavioral observations was a modification of the methodology of Kobayashi et al. [18]. Scratch counting was performed every week during the experiment period. All of the scoring was fulfilled by 2 different observers repeatedly for the exclusion of bias.

# **Histological analysis**

For histological analysis, mice were anesthetized with a high dose of Zoletil 50 (Virbac, France) on the last day of the experiment and perfused transcardially with 0.1 M phosphatebuffered saline (PBS) followed by fixation with 4% paraformaldehyde in 0.1 M PBS. Subsequently, dorsal skin tissues were removed and post-fixed for 24 h in the same fixative at 4°C. The fixed tissues were dehydrated with a graded series of alcohol concentrations before being embedded in paraffin. Paraffin-embedded tissues were sectioned using a microtome (Leica Microsystems GmbH, Germany) into 5 µm sections and then mounted onto silane-coated slides (Muto Pure Chemicals Co., Ltd, Japan). The sections were stained with hematoxylin and eosin (H&E) and toluidine blue (TB) staining according to a standard protocol. The cell density was expressed as the number of cells per 250 mm<sup>2</sup> for each section. All of the histological analysis was replicated.

# **Statistical analysis**

Statistical analyses of all data were performed using the GraphPad Prism (ver. 5.01; GraphPad, USA) statistical analysis software. The values shown represent the means of experiments performed for each experimental group. Differences among means were identified by performing Mann-Whitney and Kruskal-Wallis tests. A p < 0.05 was considered to indicate significance.



# RESULTS

## Comparison of serum IgE concentration between groups

The serum IgE concentrations among the groups were significantly different (p = 0.001). The serum IgE concentrations in the TNCB 2 weeks-treated group, TNCB 8 weeks-treated group, and the HDM-treated group were significantly different than that of the control group (p = 0.008). Moreover, the serum IgE concentration in the TNCB 2 weeks-treated (p = 0.008) and TNCB 8 weeks-treated (p = 0.016) groups were significantly different than that of the HDM-treated group. However, a comparison of the serum IgE concentrations of the TNCB 2 weeks-treated and TNCB 8 weeks-treated groups revealed no significant difference (p = 0.222) (Fig. 2).

## Comparison of serum cytokine antibody arrays between groups

Antibody array scatter plots are presented in **Fig. 3A**. The plots illustrate changes in signal intensities between the control group and the TNCB 2 weeks-treated group, between the control group and the TNCB 8 weeks-treated group, and between the control group and the HDM-treated group, with red and green lines indicating 2-fold up- or down-regulated intensities, respectively (**Fig. 3A**). The antibody array analysis identified 53 significantly up-regulated proteins in the comparison between the control and TNCB 8 weeks-treated groups (> 2-fold changes in the normalized value; *t*-test *p*-value < 0.05; **Table 1**). Between the control and HDM-treated groups, there were 5 significantly up-regulated and 3 significantly down-regulated proteins (> 2-fold changes in the normalized value; *t*-test *p* value < 0.05; **Table 2**). However, there were no significantly (fold changes > 2) up- or down-regulated proteins in the TNCB 2 weeks-treated group when compared to the control group.

All genes identified from the antibody array analysis were further analyzed according to categories within The Database for Annotation, Visualization and Integrated Discovery and the Kyoto Encyclopedia of Genes and Genomes (KEGG). Interestingly, 68 components, as determined by applying the Gene Ontology\_Biological Process (GO\_BP), in the list of proteins that were regulated by TNCB for 8 weeks were significantly enriched. Among them, the top 10 enriched GO\_BP terms were immune response, response to lipopolysaccharide, inflammatory response, chemotaxis, positive regulation of inflammatory response, wound healing, positive regulation of ERK1 and ERK2 cascades, positive regulation of MAPK



**Fig. 2.** Comparison of serum IgE concentrations between groups. The serum IgE concentrations were significantly different among the groups with the exception of the serum IgE concentrations of the TNCB 2 weeks-treated and TNCB 8 weeks-treated groups.





Fig. 3. (A) Changes in signal intensities between control and TNCB 2 weeks-treated groups, between control and TNCB 8 weeks-treated groups and between control and HDM-treated groups. (B) Functional analysis of antibody array results following TNCB treatment for 8 weeks. (C) Functional analysis of antibody array results following HDM treatment.

TNCB, trinitrochlorobenzene; HDM, house dust mite; GO\_BP, Gene Ontology\_Biological Process; KEGG, Kyoto Encyclopedia of Genes and Genomes.

cascade, positive regulation of nitric oxide biosynthetic process, and chemokine-mediated signaling pathway (**Fig. 3B**). Among KEGG categories, there were 14 pathways that were significantly enriched in the TNCB 8 weeks-treated group. Among them, cytokine-cytokine receptor interaction, Janus kinase-signal transducers and activators of transcription (Jak-STAT) signaling pathway, chemokine signaling pathway, HTLV-I infection, and inflammatory bowel disease were the top 5 enriched KEGG categories (**Fig. 3B**).



Table 1. Antibody array results for significantly changed protein in TNCB 8 weeks treated group based on foldchange rank

1      IL-9      4.977      IL-9      PIS47        2      Dtk      4.792      TYR03      PIS144        3      FGFR3      4.016      FGFR3      Q61851        4      IL-1 Ra      3.934      ILITA/      PI3432, PI3431        6      GFR alpha-4/GDNF R alpha-4      3.547      GFRA4      Q9.JT2        7      Endostatin      3.498      C0.1841      P39061        8      IL-27      3.341      IL27      Q8K36        9      IL-22      3.344      IL27      Q8K36        10      Glutz      3.226      ILRR      P14916        13      ICAM-2(CD102      3.098      ICAM2      P35330        14      CRP      3.011      CRP      P14947        15      bFGF      3.011      CRP      P14947        16      Soggy-1      2.978      DKK11      Q90219        17      CTACK      2.952      CCI7      Q91X0        18      CXCR6      2.865      IL11      P47873        20      Fri	Rank (up-regulated)	Antibody name	Fold-change	Gene symbol	Swiss-Prot entry
2      Drk      4.792      TYR03      PS5144        3      FGFR3      4.016      FGR3      Q6151        4      11-18      3.934      11.1R1      P13504        5      11-12p70      3.841      112A/B      P43431        6      GFR alpha-4/GDNF R alpha-4      3.547      GFRA      P3061        8      11-27      3.421      1127      Q81316        9      11-22      3.314      1122      Q91.179        10      Glut2      3.270      S1C2A2      P14464        11      Common gamma chain/IL-2 Rgamma      3.221      11.1R1      P14719        13      ICAM-2/CD102      3.098      ICAM2      P3530        14      CRP      3.011      FGP2      P15655        15      Soggy-1      2.952      CC127      Q9219        17      CTACK      2.952      CC127      Q92109        18      IL-11      2.855      IL11      P14477        20      Frizzled-6      2.855      FZD6      Q61089        <	1	IL-9	4.977	IL9	P15247
3      6,6R3      4,016      FGR3      0,015        4      IL-1 Ra      3,934      ILTR1      P13504        5      IL-12p70      3,841      ILT2/A,16      P43432, P43431        6      GFR alpha-4/GDNF R alpha-4      3,47      GFR4      Q9JJT2        7      Endotatin      3,481      IL27      Q8K316        8      IL-27      3,421      IL27      Q8K316        9      IL-22      3,314      IL22      Q3JJ99        10      Glut2      3,216      IL2RG      P34902        11      Common gamma chain/IL-2 R gamma      3,226      IL2RG      P34902        12      IL1 R4/S12      3,231      ILRI      P4479        13      ICAA-2 (CD02      3,938      ICAM2      P3530        14      CRP      3,011      CRM2      P350        15      bGFGF      3,011      CRM2      P350        16      Soggy-1      2,978      DKKL1      Q92L9        17      CACK6      2,854      IL11      P4773	2	Dtk	4.792	TYRO3	P55144
4      I.I.1 Ra      9.334      I.I.1R      P13042        5      II.12p70      3.811      II.12A/B      P43432, P43431        6      GFR al pha-4/GDNF R alpha-4      3.547      GFRA4      Q9.J.172        7      Endostatin      3.498      COLIBA1      P30061        8      II.27      Q8K316      P30061        9      II.22      3.314      II.27      Q8K316        9      II.22      3.314      II.27      Q8K316        10      Glut2      3.270      SLC2A2      P14464        11      Common gamma chain/IL-2 R gamma      3.221      II.1R1      P14719        13      ICAM-2/CD102      3.091      CAM2      P353        14      CRP      3.011      CAP2      P1654        15      bFGF      3.011      CAP2      P16447        15      Soggy-1      2.978      DKK11      Q9219        16      Soggy-1      2.978      DKK11      Q9219        17      CACK6      2.854      CL1P      P01447	3	FGFR3	4.016	FGFR3	Q61851
5      I.I.10p70      3.841      I.I.20,8      P4342, P4341        6      GFR alpha-/4GDNF R alpha-4      3.547      GFRA4      QJJI2        7      Endostatin      3.498      COLIBAI      P39061        8      II.27      3.421      II.27      QK3IG        9      II.22      3.214      II.22      QJJV9        10      Glut2      3.270      SLC2A2      P14246        11      Common gamma chain/II.2 R gamma      3.226      II.280      P35330        12      II.14 R/ST2      3.098      ICAM2      P35330        13      ICAM-2/CD102      3.098      ICAM2      P3555        16      Soggy-1      2.978      DKKL1      Q92L9        17      CTACK      2.981      CXCR6      QE06      QE06        18      CXCR6      2.895      II.11      P4787        20      Frizzled-6      2.854      CCL1      P1046        21      TCA-3      2.854      CL1      P1047        22      VE-cadherin      2.894      CL1	4	IL-1 Ra	3.934	IL1R1	P13504
6      GFR alpha-4/GDNF R alpha-4      3.547      GFRA4      Q9.UT2        7      Endostatin      3.498      COLIBA1      P39061        8      IL-27      3.421      IL27      Q8K316        9      IL-22      3.314      IL22      Q9.UY9        10      Glut2      3.270      SI.C2A2      P14246        11      Common gamma chain/IL-2 R gamma      3.221      IL1RL      P14719        13      ICAM-2/CD102      3.098      ICAM2      P35330        14      CRP      3.011      FGF      P14847        15      bFGF      3.011      FGF2      P15555        16      Soggy-1      2.978      DKK11      Q90219        17      CTACK      2.952      CCL27      Q921X0        18      CXC66      2.965      IL11      P47873        20      Frizzled-6      2.865      FZD6      Q61089        21      TCA-3      2.854      CCL1      P1046        22      VE-cadherin      2.804      IL16      S4824 <t< td=""><td>5</td><td>IL-12p70</td><td>3.841</td><td>IL12A/B</td><td>P43432, P43431</td></t<>	5	IL-12p70	3.841	IL12A/B	P43432, P43431
7  Endostatin  3.498  COLI8A1  P30061    8  IL-27  3.421  IL27  Q8X161    9  IL-22  3.314  IL22  Q3J.Y9    10  Glut2  3.270  SLC2A2  P14246    11  Common gamma chain/IL-2 R gamma  3.220  IL1RI  P14719    12  IL-184/ST2  3.221  IL1RI  P14719    13  ICAM-2/CD102  3.098  ICAM2  P3530    14  CPF  3.011  CRM2  P3530    15  bFGF  3.011  CRM2  P3506    16  Soggy-1  2.978  DKKL1  Q92L9    17  CTACK  2.952  CCL27  Q92I06    18  CXCR6  2.865  FZD6  Q61089    21  IT-14  2.865  IL10  P47873    20  Frizzled-6  2.865  FZD6  Q61089    21  CCL3  2.877  ICK  Q91092    23  IL-16  2.804  IL16  0.54824    24  ICK  2.677  ICK  Q9102    25  Lymphotoxin beta R/TNFR573  2.655  ITBR  P50284    26  IFN-beta <td< td=""><td>6</td><td>GFR alpha-4/GDNF R alpha-4</td><td>3.547</td><td>GFRA4</td><td>Q9JJT2</td></td<>	6	GFR alpha-4/GDNF R alpha-4	3.547	GFRA4	Q9JJT2
8      IL-27      3.421      IL27      Q8K316        9      IL-22      3.314      IL22      Q3LNY9        10      Glut2      3.270      SLC2A2      P14246        11      Common gamma chain/IL-2 R gamma      3.226      IL2RG      P34902        12      IL-1 R4/ST2      3.211      ILIRLI      P14246        13      ICAM-2/CD102      3.098      ICAM2      P35330        14      CRP      3.011      FGF2      P15655        16      Soggy-1      2.978      DKKLI      Q9Q2L9        17      CTACK      2.952      CCL27      Q921N0        18      L1-11      2.665      IL11      P47873        20      Friziled-6      2.865      FZD6      Q0169        21      TCA-3      2.854      CCL1      P1046        22      VE-cadherin      2.823      CDH5      P5284        23      IL-16      2.804      IL16      O54824        24      ICK      2.603      ICAM1      P3597        25	7	Endostatin	3.498	COL18A1	P39061
9      IL-22      3.314      IL22      9J.JY9        10      Glut2      3.270      SLC2A2      P14246        11      Common gamma chain/IL-2 R gamma      3.226      IL2RG      P34902        12      IL-1 R4/ST2      3.21      ILIRL1      P14719        13      ICAM-2/CD102      3.098      ICAM2      P3530        14      CPP      3.011      CRP      P14847        15      bFGF      3.011      FGF2      P15655        16      Soggy-1      2.978      DKK11      0.9210        17      CTACK      2.955      ICL27      0.9210        18      CXCR6      2.856      IL10      P17873        20      Friztel-6      2.865      FZD6      0.9089        21      TCA-3      2.854      CL1      P10146        22      VE-cadherin      2.804      IL16      0.54824        24      ICK      2.677      ICK      0.93KV2        25      Iymhotoxin beta /TNFRSF3      2.665      IFNB      P1575	8	IL-27	3.421	IL27	Q8K3I6
10      Glut2      3.270      SLC2A2      PI4246        11      Common gamma chain/IL-2 R gamma      3.226      IL2RG      P34902        12      IL1 R4/ST2      3.221      ILTRL1      PI4719        13      ICAM-2/CD102      3.098      ICAM2      P35330        14      CRP      3.011      CRP      PI4847        15      bF6F      3.011      CRP      PI6855        16      Soggy-1      2.978      DKkL1      Q92L9        17      CTACK      2.952      CC127      Q92R0        18      CXCR6      2.866      CXCR6      Q8EQ16        19      IL-11      2.665      IL11      P17873        20      Frizzled-6      2.864      CL1      P10146        21      TCA-3      2.854      CD1      P10146        22      VE-cadherin      2.663      LTBR      P50284        24      ICK      2.677      ICK      Q31/V2        25      Lymphotoxin beta R/TNFRSF3      2.665      LTBR      P50284	9	IL-22	3.314	IL22	Q9JJY9
11      Common gamma chain/IL-2 R gamma      3.226      IL2RG      P34902        12      IL-1 R4/ST2      3.021      ILIRL1      P14719        13      ICAM-2/CD102      3.088      ICAM2      P33330        14      CRP      3.011      CRP      P14847        15      bFGF      3.011      CRP      P14847        15      bFGF      2.978      DKKL1      Q92L9        16      Soggy-1      2.952      CL27      Q92IX0        18      CXCR6      2.865      I.11      P47873        20      Frizzled-6      2.865      I.11      P47873        21      TCA-3      2.854      CCL1      P10146        22      VE-cadherin      2.864      IL16      O54824        23      IL-16      2.804      IL16      O54824        24      ICK      2.667      ICR      P0397        25      IL97hotxin beta R/TNFRSF3      2.663      ICR      P0397        26      IFN-beta      2.643      ICAFB      Q29112	10	Glut2	3.270	SLC2A2	P14246
12      IL-1 R4/ST2      3.221      ILIRL1      PI4719        13      ICAM-2/CD102      3.098      ICAM2      P3330        14      CRP      3.011      CRP      PI4847        15      bFGF      3.011      FGF2      P15655        16      Soggy-1      2.978      DKKL1      Q9Q2L9        17      CTACK      2.952      CCL27      Q92TX0        18      CXCR6      2.865      IL11      P47873        20      Frizzled-6      2.865      FZD6      Q61089        21      TCA-3      2.854      CCL1      P10146        22      VE-cadherin      2.823      CDH5      P5284        23      IL-16      2.804      IL16      O54824        24      ICK      2.665      LTBR      P50284        25      Lymphotoxin beta R/TNFRSF3      2.665      LTBR      P50284        26      IFN-beta      2.645      IFNB1      P1575        27      CCL28      Q8UIL2      Q8UIA2        28      IA3	11	Common gamma chain/IL-2 R gamma	3.226	IL2RG	P34902
13      ICAM-2/CD102      3.098      ICAM2      P35330        14      CRP      3.011      CRP      P14847        15      bFGF      3.011      CRP      P16855        16      Soggy-1      2.978      DKKL1      Q9Q2L9        17      CTACK      2.952      CCL27      Q9ZN0        18      CXCR6      2.865      I.11      P47873        20      Frizzled-6      2.865      CDL5      Q61089        21      TCA-3      2.854      CL1      P47873        20      VE-cadherin      2.823      CDL5      P55244        21      ICK      2.665      LTB      P55244        23      IL-16      2.804      IL16      O54824        24      ICK      2.667      ICR      P50284        25      Lymphotoxin beta R/TNFRSF3      2.665      LTB      P50284        26      IFN-beta      2.643      IFNB1      P01575        27      CCL28      Q9JIL2      Q62312        28      ICAM-1      2	12	IL-1 R4/ST2	3.221	IL1RL1	P14719
14      CRP      3.011      CRP      PI4847        15      bFGF      3.011      FGF2      PI5655        16      Soggy-1      2.978      DKKL1      Q9ZL9        17      CTACK      2.952      CCL27      Q9ZIX0        18      CXCR6      2.896      CXCR6      Q9EQ16        19      IL-11      2.865      FZD6      Q61089        21      TCA-3      2.854      CCL1      P10146        22      VE-cadherin      2.804      IL16      O54824        23      IL-16      2.804      IL16      O54824        24      ICK      2.677      ICK      Q9JKV2        25      Lymphotoxin beta R/TNFRSF3      2.665      LTBR      P01575        27      CCL28      2.643      ICAM1      P10357        28      ICAM-1      2.603      ICAM1      P13597        29      TGF-beta RII      2.591      IL28      Q8212        30      CCL1/-309/TCA-3      2.511      CCL8      Q9112        31	13	ICAM-2/CD102	3.098	ICAM2	P35330
15      bFGF      3.011      FGF2      P15655        16      Soggy-1      2.978      DKKL1      Q92L9        17      CTACK      2.952      CCL27      Q921X0        18      CXCR6      2.896      CXCR6      Q9EQ16        19      IL-11      2.865      IL11      P47873        20      Frizzled-6      2.865      FZD6      Q61089        21      TCA-3      2.854      CL1      P10146        22      VE-cadherin      2.823      CDH5      P55284        23      IL-16      2.804      IL16      O54824        24      ICK      2.677      ICK      Q9JKV2        25      Lymphotoxin beta R/TNFRSF3      2.665      ITBR      P50284        26      IFN-beta      2.665      ITBR      P50284        27      CCL28      2.643      CCL2M      Q9JIL2        28      ICM-1      2.605      ITBR      P50284        29      TGF-beta RII      2.594      TGFBR2      Q60933        31	14	CRP	3.011	CRP	P14847
16      Soggy-1      2.978      DKKL1      Q9Q2L9        17      CTACK      2.952      CCL27      Q9ZIXO        18      CXCR6      2.895      CXCR6      Q9EQ16        19      IL-11      2.865      IL11      P47873        20      Frizzled-6      2.865      FZD6      Q61089        21      TCA-3      2.854      CCL1      P10146        22      VE-cadherin      2.823      CNH5      P55284        23      IL-16      2.804      IL16      O54824        24      Icymphotoxin beta R/TNFRSF3      2.665      IFN8      P50284        26      IFN-beta      2.663      IFN81      P01575        27      CCL28      2.643      CCL28      Q31/L2        28      ICAM-1      2.603      ICAM1      P13597        29      TGF-beta RI      2.504      TCFRP2      Q62312        30      CCL1/I-309/TCA-3      2.521      CCL1      P10146        31      IL-23 R      2.594      IL23R      Q81484	15	bFGF	3.011	FGF2	P15655
17      CTACK      2.952      CCL27      Q9ZIXO        18      CXCR6      2.896      CXCR6      Q9Eq16        19      IL-11      2.865      ILI1      P47873        20      Frizzled-6      2.865      FZD6      Q61089        21      TCA-3      2.854      CCL1      P10146        22      VE-cadherin      2.823      CDH5      P55284        23      IL-16      2.604      IL16      O54824        24      ICK      2.677      ICK      Q9JKV2        25      Lymphotoxin beta R/TNFRSF3      2.665      LTBR      P50284        26      IFN-beta      2.603      ICAM1      P10575        27      CCL28      Q9JIL2      Q8ZI1      P01575        28      ICAM-1      2.603      ICAM1      P13597        29      TGF-beta RI      2.504      TGFBR2      Q8ZI464        31      IL23 R      2.519      IL23R      Q8K484        32      IL17 R      2.508      IL17RA      Q60943        33 <td>16</td> <td>Soggy-1</td> <td>2.978</td> <td>DKKL1</td> <td>Q9QZL9</td>	16	Soggy-1	2.978	DKKL1	Q9QZL9
18      CXCR6      2.896      CXCR6      Q9EQ16        19      IL-11      2.865      IL11      P47873        20      Frizzled-6      2.865      FZD6      Q61089        21      TCA-3      2.854      CCL1      P10146        22      VE-cadherin      2.823      CDH5      P55284        23      IL-16      2.804      IL16      O54824        24      ICK      2.677      ICK      Q9JKV2        25      Lymphotoxin beta R/TNFRSF3      2.665      ITBR      P50284        26      IFN-beta      2.643      CCL8      Q9JIL2        28      ICAM-1      2.603      ICAM1      P13597        29      TGF-beta RI      2.594      TGFBR2      Q62312        30      CCL1/I-309/TCA-3      2.521      CCL1      P10146        31      IL-23 R      2.591      IL28 Q8CGK6        34      Prolactin      2.459      PRL      P06879        35      LIX      2.459      PRL      P06876        36 <td< td=""><td>17</td><td>CTACK</td><td>2.952</td><td>CCL27</td><td>Q9Z1X0</td></td<>	17	CTACK	2.952	CCL27	Q9Z1X0
19      IL-11      2.865      IL11      P47873        20      Frizzled-6      2.865      FZD6      Q61089        21      TCA-3      2.854      CCL1      P10146        22      VE-cadherin      2.803      CDH5      P55284        23      IL-16      2.804      IL16      O54824        24      ICK      2.677      ICK      Q9JKV2        25      Lymphotoxin beta R/TNFRSF3      2.665      LTBR      P50284        26      IFN-beta      2.643      CCL28      Q9JIL2        28      ICAM-1      2.603      ICAM1      P1357        29      TGF-beta RII      2.594      TGFBR2      Q60312        30      CCL1/1-309/TCA-3      2.519      IL23R      Q8K484        31      IL-23 R      2.508      IL17RA      Q60943        33      IL-28/IFN-lambda      2.496      IL28B      Q8CGK6        34      Prolactin      2.456      CXCL5      P50228        35      LIX      2.456      CXCL5      P50248	18	CXCR6	2.896	CXCR6	09E016
20      Frizzled-6      2.865      FZD6      Q61089        21      TCA-3      2.854      CCL1      P1046        22      VE-cadherin      2.823      CDL5      P55284        23      IL-16      2.804      IL16      O54824        24      ICK      2.677      ICK      Q9JKV2        25      Lymphotoxin beta R/TNFRSF3      2.665      ITBR      P50284        26      IFN-beta      2.643      CL28      Q9JIL2        28      ICAM-1      2.603      ICAM1      P13597        29      TGF-beta RII      2.594      TGFBR2      Q62312        30      CC1/J-309/TCA-3      2.591      IL21R      Q8484        31      IL-23 R      2.519      IL23R      Q8484        32      IL-17 R      2.508      IL17RA      Q60943        33      IL-28/IFN-lambda      2.496      IL28      Q8CGK6        34      Prolactin      2.456      CXC1      P50284        35      LIX      2.457      DCN      P84766   3	19	IL-11	2.865	IL11	P47873
21      TCA-3      2.854      CCL1      P10146        22      VE-cadherin      2.823      CDH5      P55284        23      IL-16      2.804      IL16      O54824        24      ICK      2.677      ICK      Q9JKV2        25      Lymphotoxin beta R/TNFRSF3      2.665      ITBR      P50284        26      IFN-beta      2.643      CCL28      Q9JIL2        28      ICAM-1      2.603      ICAIN      P3597        29      TGF-beta RII      2.594      TGFBR2      Q62312        30      CCL1/1-309/TCA-3      2.519      IL23R      Q8K484        31      IL-23 R      2.519      IL23R      Q8CGK6        33      IL-28/IFN-lambda      2.496      IL28      Q8CGK6        34      Prolactin      2.459      PRL      P06379        35      LIX      2.456      CXCL5      P5028        36      Follistain-like 1      2.407      FSTL1      Q62356        37      VEGF-B      2.376      DCN      P28654	20	Frizzled-6	2.865	FZD6	Q61089
22      VE-cadherin      2.823      CDH5      P55284        23      IL-16      2.804      IL16      054824        24      ICK      2.677      ICK      Q9JKV2        25      Lymphotoxin beta R/TNFRSF3      2.665      ITBR      P50284        26      IFN-beta      2.643      CCL28      Q9JIL2        28      ICAM-1      2.603      ICAM1      P13597        29      TGF-beta RII      2.594      TGFBR2      Q62312        30      CCL1/-309/TCA-3      2.591      IL23R      Q8K484        32      IL-17 R      2.508      IL17RA      Q60943        33      IL-28/IFN-lambda      2.496      IL28B      Q8CGK6        34      Prolactin      2.456      CXCL5      P50228        35      IJX      2.456      CXCL5      P5028        36      Follistatin-like 1      2.407      FSTL1      Q62356        37      VEGF-B      2.379      VEGFB      P49766        38      Decornin      2.376      DCL4      Q9WQL5	21	TCA-3	2.854	CCL1	P10146
23      IL-16      2.804      IL16      054824        24      ICK      2.677      ICK      09JKV2        25      Lymphotoxin beta R/TNFRSF3      2.665      LTBR      P50284        26      IFN-beta      2.645      IFNB1      P01575        27      CCL28      Q.643      ICAM1      P3597        28      ICAM-1      2.603      ICAM1      P3597        29      TGF-beta RII      2.594      TGFBR2      Q62312        30      CCL1/-309/TCA-3      2.591      IL7RA      Q60943        31      IL-23 R      2.519      IL17RA      Q60943        32      IL-17 R      2.508      IL17RA      Q60943        33      IL-28/IFN-lambda      2.496      IL28B      Q8CK6        34      Prolactin      2.450      CXL15      P50228        35      LIX      2.450      CXL14      Q60943        36      Pollistatin-like 1      2.407      FST1      Q62356        37      VEGF-B      2.376      DCN      P2654	22	VE-cadherin	2.823	CDH5	P55284
24      ICK      2.677      ICK      Q9JKV2        25      Lymphotoxin beta R/TNFRSF3      2.665      LTBR      P50284        26      IFN-beta      2.645      IFNB1      P01575        27      CCL28      2.643      CCL18      Q9JIL2        28      ICAM-1      2.603      ICAM1      P13597        29      TGF-beta RII      2.594      TGFBR2      Q62312        30      CCL1/I-309/TCA-3      2.521      CCL1      P10146        31      IL-23 R      2.508      IL17RA      Q60943        33      IL-28/IFN-lambda      2.496      IL28B      Q8CGK6        34      Prolactin      2.455      CXCL5      P50228        35      LIX      2.456      CXCL5      P50228        36      Follistatin-like 1      2.407      FSTL1      Q62356        37      VEGF-B      2.379      VEGFB      P49766        38      Decorin      2.376      DCN      P28643        39      CXCL14/BRAK      2.306      AGRP      956473	23	IL-16	2.804	IL16	054824
25      Lymphotoxin beta R/TNFRSF3      2.665      LTBR      P50284        26      IFN-beta      2.645      IFNB1      P01575        27      CCL28      2.643      CCL28      Q9.JIL2        28      ICAM-1      2.603      ICAM1      P13597        29      TGF-beta RII      2.594      TGFBR2      Q62312        30      CCL1/I-309/TCA-3      2.521      CCL1      P10146        31      IL-23 R      2.519      IL23R      Q8K4B4        32      IL-17 R      2.508      IL17RA      Q60943        33      IL-28/IFN-lambda      2.496      IL28B      Q8CGK6        34      Prolactin      2.455      CCL5      P50228        36      Follistatin-like 1      2.407      FSTL1      Q62356        37      VEGF-B      2.379      VEGFB      P49766        38      Decorin      2.376      DCN      P8654        39      CXCL14/BRAK      2.334      CXCL14      Q9WUQ5        40      AgRP      2.306      AGRP      Q60419	24	ICK	2.677	ICK	O9JKV2
26      IFN-beta      2.645      IFNB1      P01575        27      CCL28      2.643      CCL28      Q9JIL2        28      ICAM-1      2.603      ICAM1      P13597        29      TGF-beta RII      2.594      TGFBR2      Q62312        30      CCL1/-309/TCA-3      2.521      CCL1      P10146        31      IL-23 R      2.519      IL23R      Q8K4B4        32      IL-17 R      2.508      IL17RA      Q60943        33      IL-28/IFN-lambda      2.496      IL28B      Q8CGK6        34      Prolactin      2.456      CXCL5      P50228        36      Follistatin-like 1      2.407      FSTL1      Q62356        37      VEGF-B      2.379      VEGFB      P49766        38      Decorin      2.376      DCN      P8454        39      CXCL14/BRAK      2.334      CXCL14      Q9WUQ5        40      AgRP      2.306      AGRP      P56473        41      IL-15 R alpha      2.291      IGFBP3      P4786 <td>25</td> <td>Lymphotoxin beta R/TNFRSF3</td> <td>2,665</td> <td>LTBR</td> <td>P50284</td>	25	Lymphotoxin beta R/TNFRSF3	2,665	LTBR	P50284
27      CCL28      2.643      CCL28      Q9.JIL2        28      ICAM-1      2.603      ICAM1      P13597        29      TGF-beta RII      2.594      TGFBR2      Q62312        30      CCL1/I-309/TCA-3      2.521      CCL1      P10146        31      IL-23 R      2.519      IL23R      Q60943        32      IL-17 R      2.508      IL17RA      Q60943        33      IL-28/IFN-lambda      2.456      IL28B      Q8CK6        34      Prolactin      2.456      CXCL5      P50228        36      Follistatin-like 1      2.407      FSTL1      Q62356        37      VEGF-B      2.379      VEGFB      P49766        38      Decorin      2.376      DCN      P28654        39      CXCL14/BRAK      2.346      XCL14      Q9WQ5        40      AgRP      2.306      AGRP      P56473        41      IL-15 R alpha      2.284      IL15RA      Q60819        42      Eotaxin-2      2.251      CCL24      Q9JKCO  <	26	IFN-beta	2.645	IFNB1	P01575
28      ICAM-1      2.603      ICAM1      P13597        29      TGF-beta RII      2.594      TGFBR2      Q62312        30      CCL1/I-309/TCA-3      2.521      CCL1      P10146        31      IL-23 R      2.519      IL23R      Q8K4B4        32      IL-17 R      2.508      IL17RA      Q60943        33      IL-28/IFN-lambda      2.496      IL28B      Q8CGK6        34      Prolactin      2.459      PRL      P06879        35      LIX      2.456      CXCL5      P50228        36      Follistatin-like 1      2.407      FSTL1      Q62356        37      VEGF-B      2.379      VEGFB      P49766        38      Decorin      2.376      DCN      P28654        39      CXCL14/BRAK      2.334      CXCL14      Q9WUQ5        40      AgRP      2.306      AGRP      P56473        41      IL-15 R alpha      2.221      IGFB73      P48759        42      Eotaxin-2      2.251      CCL24      Q9JKCO <td>27</td> <td>CCL28</td> <td>2.643</td> <td>CCL28</td> <td>O9JIL2</td>	27	CCL28	2.643	CCL28	O9JIL2
29      TGF-beta RII      2.594      TGFBR2      Q62312        30      CCL1/I-309/TCA-3      2.521      CCL1      P10146        31      IL-23 R      2.519      IL23R      Q8K4B4        32      IL-17 R      2.508      IL17RA      Q60943        33      IL-28/IFN-lambda      2.496      IL28B      Q8CGK6        34      Prolactin      2.456      CXCL5      P50228        36      Follistatin-like 1      2.407      FSTL1      Q62356        37      VEGF-B      2.379      VEGFB      P49766        38      Decorin      2.376      DCN      P28654        39      CXCL14/BRAK      2.334      CXCL14      Q9WUQ5        40      AgRP      2.306      AGRP      P6473        41      IL-15 R alpha      2.284      IL15RA      Q60819        42      Eotaxin-2      2.251      CCL4      Q9WCO        43      Pentraxin3/TSG-14      2.250      PTX3      P48759        44      IGFBP-3      2.221      IGFBP3      P4787	28	ICAM-1	2.603	ICAM1	P13597
30      CCL1/I-309/TCA-3      2.521      CCL1      P10146        31      IL-23 R      2.519      IL23R      Q8K4B4        32      IL-17 R      2.508      IL17RA      Q60943        33      IL-28/IFN-lambda      2.496      IL28B      Q8CGK6        34      Prolactin      2.459      PRL      P06879        35      LIX      2.456      CXCL5      P50228        36      Follistatin-like 1      2.407      FSTL1      Q62356        37      VEGF-B      2.379      VEGFB      P49766        38      Decorin      2.376      DCN      P28654        39      CXCL14/BRAK      2.336      AGRP      P56473        41      IL-15 R alpha      2.284      IL15RA      Q60819        42      Eotaxin-2      2.251      CCL24      Q9JKCO        43      Pentraxin3/TSG-14      2.250      PTX3      P48759        44      IGFBP-3      2.221      IGFBP3      P4775        45      WISP-1/CCN4      2.179      WISP1      O54775 <td>29</td> <td>TGF-beta RII</td> <td>2.594</td> <td>TGFBR2</td> <td>062312</td>	29	TGF-beta RII	2.594	TGFBR2	062312
31      IL-23 R      2.519      IL23R      Q8K4B4        32      IL-17 R      2.508      IL17RA      Q60943        33      IL-28/IFN-lambda      2.496      IL28B      Q8CGK6        34      Prolactin      2.459      PRL      P06879        35      LIX      2.456      CXCL5      P50228        36      Follistatin-like 1      2.407      FSTL1      Q62356        37      VEGF-B      2.379      VEGFB      P49766        38      Decorin      2.376      DCN      P28654        39      CXCL14/BRAK      2.334      CXCL14      Q9WUQ5        40      AgRP      2.306      AGRP      P56473        41      IL-15 R alpha      2.284      IL15RA      Q60819        42      Eotaxin-2      2.251      CCL24      Q9JKCO        43      Pentraxin3/TSG-14      2.250      PTX3      P48759        44      IGFBP-3      2.221      IGFBP3      P47878        45      WISP-1/CCN4      2.179      WISP1      O54775 </td <td>30</td> <td>CCL1/I-309/TCA-3</td> <td>2.521</td> <td>CCL1</td> <td>P10146</td>	30	CCL1/I-309/TCA-3	2.521	CCL1	P10146
32      IL-17 R      2.508      IL17RA      Q60943        33      IL-28/IFN-lambda      2.496      IL28B      Q8CGK6        34      Prolactin      2.459      PRL      P06879        35      LIX      2.456      CXCL5      P50228        36      Follistatin-like 1      2.407      FSTL1      Q62356        37      VEGF-B      2.379      VEGFB      P49766        38      Decorin      2.376      DCN      P28654        39      CXCL14/BRAK      2.334      CXCL14      Q9WUQ5        40      AgRP      2.306      AGRP      P56473        41      IL-15 R alpha      2.284      IL15RA      Q60819        42      Eotaxin-2      2.251      CCL24      Q9JKCO        43      Pentraxin3/TSG-14      2.250      PTX3      P48759        44      IGFBP-3      2.221      IGFBP3      P47878        45      WISP1/CCN4      2.179      WISP1      O54775        46      SPARC      2.149      SPARC      P07214	31	IL-23 R	2.519	IL23R	08K4B4
33      IL-28/IFN-lambda      2.496      IL28B      Q8GGK6        34      Prolactin      2.459      PRL      P06879        35      LIX      2.456      CXCL5      P50228        36      Follistatin-like 1      2.407      FSTL1      Q62356        37      VEGF-B      2.379      VEGFB      P49766        38      Decorin      2.376      DCN      P28654        39      CXCL14/BRAK      2.334      CXCL14      Q9WUQ5        40      AgRP      2.306      AGRP      P56473        41      IL-15 R alpha      2.284      IL15RA      Q60819        42      Eotaxin-2      2.251      CCL24      Q9JKC0        43      Pentraxin3/TSG-14      2.250      PTX3      P48759        44      IGFBP-3      2.221      IGFBP3      P47878        45      WISP-1/CCN4      2.179      WISP1      054775        46      SPARC      2.130      MSTN      008689        48      HVEM/TNFRSF14      2.069      TNFRSF14      NP_001037847<	32	IL-17 R	2.508	IL17RA	060943
34      Prolactin      2.459      PRL      P06879        35      LlX      2.456      CXCL5      P50228        36      Follistatin-like 1      2.407      FSTL1      Q62356        37      VEGF-B      2.379      VEGFB      P49766        38      Decorin      2.376      DCN      P28654        39      CXCL14/BRAK      2.334      CXCL14      Q9WUQ5        40      AgRP      2.306      AGRP      P56473        41      IL-15 R alpha      2.284      IL15RA      Q60819        42      Eotaxin-2      2.251      CCL24      Q9JKC0        43      Pentraxin3/TSG-14      2.250      PTX3      P48759        44      IGFBP-3      2.221      IGFBP3      P47878        45      WISP-1/CCN4      2.179      WISP1      O54775        46      SPARC      2.149      SPARC      P07214        47      GDF-8      2.130      MSTN      008689        48      HVEM/TNFRSF14      2.069      TNFRSF14      NP_401037847 </td <td>33</td> <td>IL-28/IFN-lambda</td> <td>2.496</td> <td>IL28B</td> <td>Q8CGK6</td>	33	IL-28/IFN-lambda	2.496	IL28B	Q8CGK6
35      LIX      2.456      CXCL5      P50228        36      Follistatin-like 1      2.407      FSTL1      Q62356        37      VEGF-B      2.379      VEGFB      P49766        38      Decorin      2.376      DCN      P28654        39      CXCL14/BRAK      2.334      CXCL14      Q9WUQ5        40      AgRP      2.306      AGRP      P56473        41      IL-15 R alpha      2.284      IL15RA      Q60819        42      Eotaxin-2      2.251      CCL24      Q9JKC0        43      Pentraxin3/TSG-14      2.250      PTX3      P48759        44      IGFBP-3      2.221      IGFBP3      P47878        45      WISP-1/CCN4      2.179      WISP1      O54775        46      SPARC      2.149      SPARC      P07214        47      GDF-8      2.130      MSTN      008689        48      HVEM/TNFRSF14      2.069      TNFRSF14      NP_849262        49      EG-VEGF/PK1      2.060      IL27RA      070394	34	Prolactin	2.459	PRL	P06879
Initial      Initial      Initial      Operation        36      Follistatin-like 1      2.407      FSTL1      Q62356        37      VEGF-B      2.379      VEGFB      P49766        38      Decorin      2.376      DCN      P28654        39      CXCL14/BRAK      2.334      CXCL14      Q9WUQ5        40      AgRP      2.306      AGRP      P56473        41      IL-15 R alpha      2.284      IL15RA      Q60819        42      Eotaxin-2      2.251      CCL24      Q9JKCO        43      Pentraxin3/TSG-14      2.250      PTX3      P48759        44      IGFBP-3      2.221      IGFBP3      P47878        45      WISP-1/CCN4      2.179      WISP1      O54775        46      SPARC      2.149      SPARC      P07214        47      GDF-8      2.130      MSTN      008689        48      HVEM/TNFRSF14      2.069      TNFRSF14      NP_849262        49      EG-VEGF/PK1      2.060      IL27RA      070394	35	LIX	2.456	CXCL5	P50228
37      VEGF-B      2.379      VEGFB      P49766        38      Decorin      2.376      DCN      P28654        39      CXCL14/BRAK      2.334      CXCL14      Q9WUQ5        40      AgRP      2.306      AGRP      P56473        41      IL-15 R alpha      2.284      IL15RA      Q60819        42      Eotaxin-2      2.251      CCL24      Q9JKCO        43      Pentraxin3/TSG-14      2.250      PTX3      P48759        44      IGFBP-3      2.221      IGFBP3      P47878        45      WISP-1/CCN4      2.179      WISP1      O54775        46      SPARC      2.149      SPARC      P07214        47      GDF-8      2.130      MSTN      008689        48      HVEM/TNFRSF14      2.069      TNFRSF14      NP_849262        49      EG-VEGF/PK1      2.060      IL27RA      070394        50      TCCR/WSX-1      2.060      IL27RA      070394        51      TLR2      2.030      TNFRSF12A      Q9CN75 </td <td>36</td> <td>Follistatin-like 1</td> <td>2.407</td> <td>FSTL1</td> <td>O62356</td>	36	Follistatin-like 1	2.407	FSTL1	O62356
1      1	37	VEGE-B	2.379	VEGEB	P49766
39      CXCL14/BRAK      2.334      CXCL14      Q9VUQ5        40      AgRP      2.306      AGRP      P56473        41      IL-15 R alpha      2.284      IL15RA      Q60819        42      Eotaxin-2      2.251      CCL24      Q9JKC0        43      Pentraxin3/TSG-14      2.250      PTX3      P48759        44      IGFBP-3      2.221      IGFBP3      P47878        45      WISP-1/CCN4      2.179      WISP1      O54775        46      SPARC      2.149      SPARC      P07214        47      GDF-8      2.130      MSTN      008689        48      HVEM/TNFRSF14      2.069      TNFRSF14      NP_849262        49      EG-VEGF/PK1      2.068      PROK1      NP_001037847        50      TCCR/WSX-1      2.060      IL27RA      070394        51      TLR2      2.050      TLR2      Q9QUN7        52      TWEAK R/TNFRSF12      2.030      TNFRSF12A      Q9CR75        53      PF-4      2.003      PF4      Q9Z126<	38	Decorin	2.376	DCN	P28654
40      AgRP      2.306      AGRP      P56473        41      IL-15 R alpha      2.284      IL15RA      Q60819        42      Eotaxin-2      2.251      CCL24      Q9JKCO        43      Pentraxin3/TSG-14      2.250      PTX3      P48759        44      IGFBP-3      2.221      IGFBP3      P47878        45      WISP-1/CCN4      2.179      WISP1      O54775        46      SPARC      2.149      SPARC      P07214        47      GDF-8      2.130      MSTN      008689        48      HVEM/TNFRSF14      2.069      TNFRSF14      NP_849262        49      EG-VEGF/PK1      2.068      PROK1      NP_001037847        50      TCCR/WSX-1      2.060      IL27RA      070394        51      TLR2      2.050      TLR2      Q9QUN7        52      TWEAK R/TNFRSF12      2.030      TNFRSF12A      Q9CR75        53      PF-4      2.003      PF4      Q9Z126	39	CXCL14/BRAK	2.334	CXCL14	09WU05
41      IL1S R alpha      2.284      IL1S RA      Q60819        42      Eotaxin-2      2.251      CCL24      Q9JKCO        43      Pentraxin3/TSG-14      2.250      PTX3      P48759        44      IGFBP-3      2.221      IGFBP3      P47878        45      WISP-1/CCN4      2.179      WISP1      O54775        46      SPARC      2.149      SPARC      P07214        47      GDF-8      2.130      MSTN      O08689        48      HVEM/TNFRSF14      2.069      TNFRSF14      NP_849262        49      EG-VEGF/PK1      2.068      PROK1      NP_001037847        50      TCCR/WSX-1      2.060      IL27RA      070394        51      TLR2      2.050      TLR2      Q9QUN7        52      TWEAK R/TNFRSF12      2.030      TNFRSF12A      Q9CR75        53      PF-4      2.003      PF4      Q9Z126	40	AgRP	2.306	AGRP	P56473
42      Eotaxin-2      2.251      CCL24      QJKCO        43      Pentraxin3/TSG-14      2.250      PTX3      P48759        44      IGFBP-3      2.221      IGFBP3      P47878        45      WISP-1/CCN4      2.179      WISP1      O54775        46      SPARC      2.149      SPARC      P07214        47      GDF-8      2.130      MSTN      O08689        48      HVEM/TNFRSF14      2.069      TNFRSF14      NP_849262        49      EG-VEGF/PK1      2.068      PROK1      NP_001037847        50      TCCR/WSX-1      2.060      IL27RA      070394        51      TLR2      2.050      TLR2      Q9QUN7        52      TWEAK R/TNFRSF12      2.030      TNFRSF12A      Q9CR75        53      PF-4      2.003      PF4      Q9Z126	41	IL-15 R alpha	2.284	IL15RA	060819
43      Pentraxin3/TSG-14      2.250      PTx3      P48759        44      IGFBP-3      2.221      IGFBP3      P47878        45      WISP-1/CCN4      2.179      WISP1      O54775        46      SPARC      2.149      SPARC      P07214        47      GDF-8      2.130      MSTN      008689        48      HVEM/TNFRSF14      2.069      TNFRSF14      NP_849262        49      EG-VEGF/PK1      2.068      PROK1      NP_001037847        50      TCCR/WSX-1      2.060      IL27RA      070394        51      TLR2      2.050      TLR2      Q9QUN7        52      TWEAK R/TNFRSF12      2.030      TNFRSF12A      Q9CR75        53      PF-4      2.003      PF4      Q9Z126	42	Eotaxin-2	2.251	CCL24	09JKC0
44      IGFBP-3      2.221      IGFBP3      P47878        45      WISP-1/CCN4      2.179      WISP1      O54775        46      SPARC      2.149      SPARC      P07214        47      GDF-8      2.130      MSTN      O08689        48      HVEM/TNFRSF14      2.069      TNFRSF14      NP_849262        49      EG-VEGF/PK1      2.068      PROK1      NP_001037847        50      TCCR/WSX-1      2.060      IL27RA      070394        51      TLR2      2.050      TLR2      Q9QUN7        52      TWEAK R/TNFRSF12      2.030      TNFRSF12A      Q9CR75        53      PF-4      2.003      PF4      Q9Z126	43	Pentraxin3/TSG-14	2.250	PTX3	P48759
45      WISP-1/CCN4      2.179      WISP1      054775        46      SPARC      2.149      SPARC      P07214        47      GDF-8      2.130      MSTN      008689        48      HVEM/TNFRSF14      2.069      TNFRSF14      NP_849262        49      EG-VEGF/PK1      2.068      PROK1      NP_001037847        50      TCCR/WSX-1      2.060      IL27RA      070394        51      TLR2      2.050      TLR2      Q9QUN7        52      TWEAK R/TNFRSF12      2.030      TNFRSF12A      Q9CR75        53      PF-4      2.003      PF4      Q9Z126	44	IGFBP-3	2.221	IGFBP3	P47878
46      SPARC      P07214        47      GDF-8      2.130      MSTN      008689        48      HVEM/TNFRSF14      2.069      TNFRSF14      NP_849262        49      EG-VEGF/PK1      2.068      PROK1      NP_001037847        50      TCCR/WSX-1      2.060      IL27RA      070394        51      TLR2      2.030      TNFRSF12A      Q9QUN7        52      TWEAK R/TNFRSF12      2.030      TNFRSF12A      Q9CR75        53      PF-4      2.003      PF4      Q9Z126	45	WISP-1/CCN4	2.179	WISP1	054775
47      GDF-8      2.130      MSTN      008689        48      HVEM/TNFRSF14      2.069      TNFRSF14      NP_849262        49      EG-VEGF/PK1      2.068      PROK1      NP_001037847        50      TCCR/WSX-1      2.060      IL27RA      070394        51      TLR2      2.050      TLR2      Q9QUN7        52      TWEAK R/TNFRSF12      2.030      TNFRSF12A      Q9CR75        53      PF-4      2.003      PF4      Q9Z126	46	SPARC	2.149	SPARC	P07214
48      HVEM/TNFRSF14      2.069      TNFRSF14      NP_849262        49      EG-VEGF/PK1      2.068      PROK1      NP_001037847        50      TCCR/WSX-1      2.060      IL27RA      070394        51      TLR2      2.050      TLR2      Q9QUN7        52      TWEAK R/TNFRSF12      2.030      TNFRSF12A      Q9CR75        53      PF-4      2.003      PF4      Q9Z126	47	GDF-8	2.130	MSTN	008689
49  EG-VEGF/PK1  2.068  PROK1  NP_001037847    50  TCCR/WSX-1  2.060  IL27RA  070394    51  TLR2  2.050  TLR2  Q9QUN7    52  TWEAK R/TNFRSF12  2.030  TNFRSF12A  Q9CR75    53  PF-4  2.003  PF4  Q9Z126	48	HVFM/TNFRSF14	2.069	TNFRSF14	NP 849262
50      TCCR/WSX-1      2.060      IL27RA      070394        51      TLR2      2.050      TLR2      Q9QUN7        52      TWEAK R/TNFRSF12      2.030      TNFRSF12A      Q9CR75        53      PF-4      2.003      PF4      Q9Z126	49	EG-VEGF/PK1	2.068	PROK1	NP 001037847
51      TLR2      2.050      TLR2      Q9QUN7        52      TWEAK R/TNFRSF12      2.030      TNFRSF12A      Q9CR75        53      PF-4      2.003      PF4      Q9Z126	50	TCCR/WSX-1	2.060	IL27RA	070394
52      TWEAK R/TNFRSF12      2.003      TNFRSF12A      Q9CR75        53      PF-4      2.003      PF4      Q9Z126	51	TLR2	2.050	TLR2	090UN7
53 PF-4 2.003 PF4 Q9Z126	52	TWEAK R/TNFRSF12	2.030	TNFRSF12A	09CR75
	53	PF-4	2.003	PF4	Q9Z126

TNCB, trinitrochlorobenzene; IL, interleukin.

In the GO\_BP results for the HDM-treated group, 30 components among the list of proteins that were regulated by HDM were significantly enriched. Among them, the top 10 enriched GO\_BP terms were immune response, positive regulation of tyrosine phosphorylation of



Table 2. Antibe	by array results for significantly en			ied off fold change failk
Rank	Antibody name	Fold-change	Gene symbol	Swiss-Prot entry
Up-regulated				
1	IL-12p70	3.112	IL12A/B	P43432, P43431
2	MIP-1gamma	2.322	CCL9	P51670
3	NOV/CCN3	2.302	NOV	Q64299
4	Thymus chemokine-1	2.210	PPBP	Q9EQI5
5	RAGE	2.027	RAGE	Q9WVS4
Down-regulate	d			
1	IL-9	0.169	IL9	P15247
2	Dtk	0.219	TYRO3	P55144
3	FGF R3	0.347	FGFR3	Q61851

Table 2. Antibody array results for significantly changed protein in HDM treated group based on fold-change rank

HDM, house dust mite; IL, interleukin.

STAT4 protein, positive regulation of mononuclear cell proliferation, positive regulation of NK T cell activation, positive regulation of natural killer cell-mediated cytotoxicity directed against tumor cell target, response to UV-B, positive regulation of lymphocyte proliferation, positive regulation of the smooth muscle cell apoptotic process, positive regulation of natural killer cell activation, and negative regulation of interleukin (IL)-17 production (**Fig. 3C**). Among the KEGG results, there were 15 pathways that were significantly enriched in the HDM-treated group. Among them, cytokine-cytokine receptor interaction, Jak-STAT signaling pathway, African trypanosomiasis, allograft rejection, and legionellosis were the top 5 enriched KEGG categories (**Fig. 3C**).

## Comparison of skin lesion scores between groups

Clinical symptoms including erythema/hemorrhage, scarring/dryness, edema, and excoriation/erosion were most serious in the TNCB 2 weeks-treated group (**Fig. 4A**). The scoring of skin lesions among the groups showed significant differences (p = 0.0007). The skin lesion scoring results in the TNCB 2 weeks-treated group (p = 0.0097), TNCB 8 weeks-treated group (p = 0.0097) and the HDM-treated group (p = 0.0097) were significantly different from that of the control group. Moreover, the skin lesion scores in the TNCB 8 weeks-treated group (p = 0.0112) and the HDM-treated group (p = 0.0112) were significantly different from that in the TNCB 2 weeks-treated group. However, a comparison of the skin lesion scores between the TNCB 8 weeks-treated group and the HDM-treated group failed to detect a significant difference (p = 0.136) (**Fig. 4B**).

## Comparison of scratching frequencies between groups

The scratching frequencies of the groups were significantly different (p = 0.0007). The scratching frequencies in the TNCB 2 weeks-treated group (p = 0.0097), TNCB 8 weeks-treated group (p = 0.0097) and HDM-treated group (p = 0.0097) were significantly different from that of the control group. Moreover, the scratching frequencies in the TNCB 8 weeks-treated group (p = 0.0119) and the HDM-treated group (p = 0.0119) were significantly different from that of TNCB 2 weeks-treated group. In addition, a comparison of the scratching frequencies of the TNCB 8 weeks-treated group HDM-treated group showed the presence of a significant difference (p = 0.0112) (**Fig. 4C**).

## Comparison of histological results between groups

The H&E staining of control group tissue revealed normal structures within the epidermis, dermis, subcutaneous layer, and muscle layer. Compared to the control group tissue, epidermal and dermal hyperplasia, excessive keratinization, and infiltration of lymphocytes were exhibited in the TNCB 2 weeks-treated group. In the TNCB 8 weeks-treated and HDM-treated groups,





**Fig. 4.** (A) Representative clinical features in control, TNCB 2 weeks-treated, TNCB 8 weeks-treated and HDM-treated groups. (B) Dermatitis scores of the groups were significantly different except the scores of the TNCB 8 weeks-treated and HDM-treated groups were similar. (C) Scratching frequencies of the groups were significantly different. (D) Inflammatory cells (white arrow) were excessively exhibited in the TNCB 2 weeks-treated group. Mast cells (black arrow) in the dermis were excessively exhibited in the TNCB 8 weeks-treated group. Scale bar indicated 250  $\mu$ m. (E) The mast cell density was expressed as the number of cells per 250  $\mu$ m<sup>2</sup> for each section. The significantly different was indicated between groups of the mast cells density. TNCB, trinitrochlorobenzene; HDM, house dust mite. \*p < 0.05; \*\*p < 0.01.

p < 0.03, p < 0.01.



there was skin damage from the epithelium to the dermis, but the infiltration of lymphocytes was less than that exhibited by the TNCB 2 weeks-treated group tissues (**Fig. 4D**).

The TB staining results showed that the number of mast cells in the dermis was higher in the TCNB 8 weeks-treated (p = 0.0005, 0.0006) and HDM-treated groups (p = 0.0004, 0.0004) than that in the dermis of the control group and TNCB 2 weeks-treated group, each (**Fig. 4D and E**).

# DISCUSSION

There have been many studies into establishing AD models [8-10] useful in elucidating the pathologies and development of AD. However, there are few reports comparing AD models. In this study, we established Nc/Nga mouse AD models that were induced with either TNCB for short (2 weeks) and long (8 weeks) periods or with HDM and compared the effects in each of the groups.

Recently, the possibility that repeated application of haptens, such as TNCB or oxazolone, over an extended period can cause skin inflammation to shift from a typical Th1-dominated delayed-type hypersensitivity response to a chronic Th2-dominated inflammatory response has been suggested [10,19]. In this study, we observed notably different results between the short and long periods of TNCB treatment. Even though the serum IgE concentration, which was produced by B cells, was not significantly different between TNCB treatment periods, cytokine antibody array analysis, dermatitis score, and scratching frequency were significantly different between the short and long TNCB treatment periods. Moreover, antibody array analysis, which analyzed 308 cytokines, showed there were no cytokines exhibiting fold changes greater than 2 (compared to the control group) in the TNCB 2 weeks-treated group. However, in the comparison of the TNCB 8 weeks-treated group and the control group, there were 53 significantly up-regulated proteins following the long period (8 weeks) of TNCB treatment.

Among the significantly up-regulated proteins, the expression of IL-9 was the highest observed in the TNCB 8 weeks-treated group. IL-9 is a pleiotropic cytokine (cell signaling molecule) produced by various cells, including mast, NK T, Th2, Th9, Th17, and regulatory T cells. In combination with the IL-9 receptor, it exerts a variety of biological functions through the STAT pathway [20]. There are diverse opinions about the effect of IL-9 expression in AD. Previous studies have described the proliferation of Th9 cells and the expression of IL-9 in allergic respiratory diseases, asthma, and rhinitis [21]. In one study, observation of increasing expression of IL-9 and proliferation of Th9 cells in human AD suggested that they can perform the potential roles of Th2 cells in AD [22]. Similarly, another study showed that the serum IL-9 level in patients with AD was higher than that in normal human children [23]. On the other hand, there was a study that showed a decrease in the IL-9-enhanced Th1 response in AD [21]. The results of cytokine array analysis in the present study support the hypothesis that TNCB treatment over an extended period can cause skin inflammation to shift from a typical Th1-dominated delayed-type hypersensitivity response to a chronic Th2-dominated inflammatory response [10,19].

The studies related HDM induced AD in Nc/Nga mice could not solve the pathogenesis clearly. They confirmed that application of a HDM extract to the skin of Nc/Nga mice can



increase the clinical, histological symptoms and serum IgE concentration [15,24,25]. One of the study showed that the expressions of Th1/Th2/Th17 related cytokines were increased in HDM induced AD in Nc/Nga mice [15]. In this study, we confirmed similar results with the previous studies. Interestingly, even though the patterns of serum IgE concentrations, skin lesion scores, and histological results in the TNCB 8 weeks-treated group were similar to the patterns in the HDM-treated group, the expression of IL-9, based on cytokine array analysis, was lowest in HDM-treated group. We assumed that the AD patterns induced by repeated long-period TNCB treatment would be similar with the AD patterns induced by HDM treatment based on the serum IgE concentration, scoring of skin lesions, and histological analysis results, but are unable to explain the inflammatory response to the HDM treatment because IL-9 was the lowest in the HDM-treated group.

The scratch scoring results showed that scratch frequency was the highest in the HDM treatment group, although the serum IgE concentration was the highest in the TNCB 2 weeks-treated group. Based on these results, we assume that HDM induced scratching behavior via IgE-independent mechanisms. Yamada et al. [15] also observed that HDM-induced scratching behavior was not related to IgE concentration.

Based on this study, we confirm that the immunological patterns of each AD-induced animal model group were different; even treatment duration could produce a different immune response in an AD-induced animal model.

# **ACKNOWLEDGEMENTS**

We Thank Miss Cho JW, Lee HW, Woo JW and Kim HJ for helpful experiments.

# REFERENCES

- Gittler JK, Krueger JG, Guttman-Yassky E. Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis. J Allergy Clin Immunol. 2013;131(2):300-313.
   PUBMED | CROSSREF
- 2. Halliwell R. Revised nomenclature for veterinary allergy. Vet Immunol Immunopathol. 2006;114(3-4):207-208. PUBMED | CROSSREF
- Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest. 2004;113(5):651-657.
   PUBMED I CROSSREF
- Novak N, Bieber T, Leung DY. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol. 2003;112(6 Suppl):S128-S139.
   PUBMED | CROSSREF
- Fartasch M. Epidermal barrier in disorders of the skin. Microsc Res Tech. 1997;38(4):361-372.
  PUBMED | CROSSREF
- Takaoka A, Arai I, Sugimoto M, Honma Y, Futaki N, Nakamura A, et al. Involvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like dermatitis. Exp Dermatol. 2006;15(3):161-167.
   PUBMED | CROSSREF
- Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(2):336-349.
   PUBMED | CROSSREF
- Spergel JM, Mizoguchi E, Brewer JP, Martin TR, Bhan AK, Geha RS. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest. 1998;101(8):1614-1622.
   PUBMED | CROSSREF



- Kimura M, Tsuruta S, Yoshida T. Correlation of house dust mite-specific lymphocyte proliferation with IL-5 production, eosinophilia, and the severity of symptoms in infants with atopic dermatitis. J Allergy Clin Immunol. 1998;101(1 Pt 1):84-89.
   PUBMED | CROSSREF
- Matsumoto K, Mizukoshi K, Oyobikawa M, Ohshima H, Tagami H. Establishment of an atopic dermatitislike skin model in a hairless mouse by repeated elicitation of contact hypersensitivity that enables to conduct functional analyses of the stratum corneum with various non-invasive biophysical instruments. Skin Res Technol. 2004;10(2):122-129.
   PUBMED | CROSSREF
- 11. Jin H, He R, Oyoshi M, Geha RS. Animal models of atopic dermatitis. J Invest Dermatol. 2009;129(1):31-40. PUBMED | CROSSREF
- Matsuda H, Watanabe N, Geba GP, Sperl J, Tsudzuki M, Hiroi J, et al. Development of atopic dermatitislike skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol. 1997;9(3):461-466.
   PUBMED | CROSSREF
- Martel BC, Lovato P, Bäumer W, Olivry T. Translational animal models of atopic dermatitis for preclinical studies. Yale J Biol Med 2017;90(3):389-402.
- Lee HJ, Lee NR, Jung M, Kim DH, Choi EH. Atopic march from atopic dermatitis to asthma-like lesions in NC/Nga mice is accelerated or aggravated by neutralization of stratum corneum but partially inhibited by acidification. J Invest Dermatol. 2015;135(12):3025-3033.
- Yamada Y, Ueda Y, Nakamura A, Kanayama S, Tamura R, Hashimoto K, et al. Biphasic increase in scratching behaviour induced by topical application of *Dermatophagoides farinae* extract in NC/Nga mice. Exp Dermatol. 2016;25(8):611-617.
- Takahashi N, Arai I, Honma Y, Hashimoto Y, Harada M, Futaki N, et al. Scratching behavior in spontaneous- or allergic contact-induced dermatitis in NC/Nga mice. Exp Dermatol. 2005;14(11):830-837.
   PUBMED | CROSSREF
- Suto H, Matsuda H, Mitsuishi K, Hira K, Uchida T, Unno T, et al. NC/Nga mice: a mouse model for atopic dermatitis. Int Arch Allergy Immunol. 1999;120 Suppl 1:70-75.
- Kobayashi Y, Takahashi R, Ogino F. Antipruritic effect of the single oral administration of German chamomile flower extract and its combined effect with antiallergic agents in ddY mice. J Ethnopharmacol. 2005;101(1-3):308-312.
   PUBMED | CROSSREF
- Man MQ, Hatano Y, Lee SH, Man M, Chang S, Feingold KR, et al. Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges. J Invest Dermatol. 2008;128(1):79-86.
   PUBMED | CROSSREF
- Soussi-Gounni A, Kontolemos M, Hamid Q. Role of IL-9 in the pathophysiology of allergic diseases. J Allergy Clin Immunol. 2001;107(4):575-582.
   PUBMED I CROSSREF
- Liu J, Harberts E, Tammaro A, Girardi N, Filler RB, Fishelevich R, et al. IL-9 regulates allergen-specific Th1 responses in allergic contact dermatitis. J Invest Dermatol. 2014;134(7):1903-1911.
   PUBMED | CROSSREF
- Ma L, Xue HB, Guan XH, Shu CM, Zhang JH, Yu J. Possible pathogenic role of T helper type 9 cells and interleukin (IL)-9 in atopic dermatitis. Clin Exp Immunol. 2014;175(1):25-31.
   PUBMED | CROSSREF
- Ciprandi G, De Amici M, Giunta V, Marseglia A, Marseglia G. Serum interleukin-9 levels are associated with clinical severity in children with atopic dermatitis. Pediatr Dermatol. 2013;30(2):222-225.
   PUBMED | CROSSREF
- Yamamoto M, Haruna T, Ueda C, Asano Y, Takahashi H, Iduhara M, et al. Contribution of itch-associated scratch behavior to the development of skin lesions in *Dermatophagoides farinae*-induced dermatitis model in NC/Nga mice. Arch Dermatol Res. 2009;301(10):739-746.
   PUBMED | CROSSREF
- Yamamoto M, Haruna T, Yasui K, Takahashi H, Iduhara M, Takaki S, et al. A novel atopic dermatitis model induced by topical application with *Dermatophagoides farinae* extract in NC/Nga mice. Allergol Int. 2007;56(2):139-148.
   PUBMED | CROSSREF